GLP-1 Therapy, NAD+, and the Metabolic Compounds Patients Ask About Most
Semaglutide and tirzepatide changed the conversation around weight and metabolic health faster than almost any therapy in recent memory, and the next generation, retatrutide, is already showing larger effects in trial data. NAD+ sits alongside them for a different reason, it's central to mitochondrial energy production and one of the most commonly misunderstood therapies in the longevity space.
Signals First, Symptoms Second
GLP-1/GIP/glucagon receptor agonists and NAD+ both act on core metabolic and mitochondrial machinery, not just an appetite switch or an energy buzzword. The full reasoning behind evaluating them that way is on the Cellular Medicine page.
GLP-1 Therapies, NAD+, Lipid Supplements, 5-Amino-1MQ, SLU-PP-332, and Tesofensine
Liraglutide
The once-daily GLP-1 agonist that came before semaglutide, with a real placebo-controlled cardiovascular trial but head-to-head data showing less weight loss and glycemic benefit than the once-weekly drugs that followed it.
Read the Guide GLP-1Semaglutide
The GLP-1 receptor agonist that started this category, covered through its actual randomized trial evidence on weight and cardiovascular outcomes.
Read the Guide GIP/GLP-1Tirzepatide
A dual GIP/GLP-1 receptor agonist with head-to-head trial data against semaglutide and a dedicated body-composition sub-study.
Read the Guide GIP/GLP-1/GlucagonRetatrutide
A triple-receptor agonist in Phase 3 trials, with reported weight-loss outcomes exceeding tirzepatide's.
Read the Guide MitochondrialNAD+
The redox cofactor mitochondria depend on for ATP production, including a recent real-world comparison of IV NAD+ against IV NR that runs counter to common clinic marketing.
Read the Guide NNMT Inhibitor5-Amino-1MQ
A small-molecule NNMT inhibitor with real mouse data on fat mass and aged muscle, but zero human trials to date.
Read the Guide ERR Agonist / Exercise MimeticSLU-PP-332
A synthetic pan-ERR agonist with real mouse data on exercise capacity and metabolic syndrome, a newer oral analog, and the first human-cell evidence, but still zero completed human trials.
Read the Guide Lipid PanelBlood Lipid Supplements
A look at seven supplements with real human trial evidence on LDL and triglycerides, and the widely used one that improves the numbers but has twice failed in cardiovascular outcome trials.
Read the Guide Appetite RegulationTesofensine
A triple monoamine reuptake inhibitor with real trial data in general obesity, hypothalamic obesity, and Prader-Willi syndrome, and a cardiovascular signal that a specific combination product was built to address.
Read the GuideAlso Relevant Here
Thyroid hormone and Tesamorelin both have real metabolic and body-composition angles beyond their primary categories.
Common Questions
Have a Question, or Want to Find a Clinic?
If you're already a patient, bring this up with your care team at your next visit. If you're not a patient yet and want to ask a question first, or find one of our clinics, reach out directly.